logo
Twitter
Discord
Email
logo
Perrigo Company plc

Perrigo Company plc

NYSE•PRGO
CEO: Mr. Patrick Lockwood-Taylor
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1991-12-17
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Contact Information
The Sharp Building, Hogan Place, Dublin, D02 TY74, Ireland
353-1-709-4000
www.perrigo.com
Market Cap
$1.77B
P/E (TTM)
-34.3
81.2
Dividend Yield
9.0%
52W High
$30.93
52W Low
$12.17
52W Range
4%
Rank48Top 50.7%
3.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$1.04B-4.06%
4-Quarter Trend

EPS

$0.05-133.33%
4-Quarter Trend

FCF

$29.80M+97.35%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Operating Income Rebounds Strongly Nine months operating income reached $164.9M, reversing prior year's $1.3M loss; Gross margin improved 20 basis points to 36.0%.
CSCA/CSCI Segment Profitability CSCA operating income $203.7M; CSCI operating income $136.2M, showing strong profit flow-through across segments.
Cash Flow from Operations Operating cash flow increased $12.8M to $63.1M for nine months, driven by improved net loss position and adjustments.
Tax Law Benefit Realized OBBBA enactment estimated to provide $28.0M tax benefit for 2025, improving realizability of deferred tax assets.

Risk Factors

Divestiture/Impairment Charges Recorded $1.2M goodwill impairment for Richard Bittner sale; Dermacosmetics assets held for sale as of September 2025.
Macroeconomic Volatility Risks Ongoing uncertainty from tariffs, geopolitical conflicts, and inflation may increase COGS by $10M-$20M in Q4 2025.
Ongoing Price-Fixing Litigation Price-fixing lawsuits remain active; court opinion issued but final judgment pending resolution of potential adverse impacts.
Infant Formula Remediation Costs Remediation costs for Wisconsin facility reached approximately $22.6M cash costs, impacting output and market share recovery.

Outlook

Project Energize Savings Expected Project Energize targets $140M to $170M pre-tax savings by end of 2026, with substantial costs incurred by end of 2025.
Strategic Review of Infant Formula Strategic review announced for infant formula business in November 2025, assessing alternatives and optimizing portfolio focus.
Supply Chain Reinvention Progress Supply Chain Reinvention aims for $200M to $300M run-rate savings by 2028; $150M to $200M expected by end of 2025.
Dermacosmetics Sale Expected Dermacosmetics Business sale expected to close in the first quarter of 2026, subject to regulatory approvals.

Peer Comparison

Revenue (TTM)

Perrigo Company plcPRGO
$4.28B
-2.5%
Amneal Pharmaceuticals, Inc.AMRX
$2.93B
+9.5%
ICU Medical, Inc.ICUI
$2.32B
-0.8%

Gross Margin (Latest Quarter)

Tarsus Pharmaceuticals, Inc.TARS
93.0%
-0.3pp
Supernus Pharmaceuticals, Inc.SUPN
90.1%
+11.6pp
Indivior PLCINDV
73.2%
-4.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
INDV$4.40B26.5-60.4%3.7%
AMRX$3.92B663.75.1%74.6%
ICUI$3.65B-627.9-0.3%32.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.9%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:$0.81
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 27, 2025|Filed: Nov 5, 2025|
    Revenue: $1.04B-4.1%
    |
    EPS: $0.05-133.3%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 28, 2025|Filed: Aug 6, 2025|
    Revenue: $1.06B-0.9%
    |
    EPS: $-0.06-92.1%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 29, 2025|Filed: May 7, 2025|
    Revenue: $1.04B-3.5%
    |
    EPS: $-0.05-600.0%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|
    Revenue: $4.37B-6.1%
    |
    EPS: $-1.25-1231.2%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 28, 2024|Filed: Nov 6, 2024|
    Revenue: $1.09B-3.2%
    |
    EPS: $-0.15-236.4%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 29, 2024|Filed: Aug 2, 2024|
    Revenue: $1.07B-10.7%
    |
    EPS: $-0.77-1270.2%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 30, 2024|Filed: May 7, 2024|
    Revenue: $1.08B-8.4%
    |
    EPS: $0.01-222.0%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 27, 2024|
    Revenue: $4.66B+4.6%
    |
    EPS: $-0.09+90.3%
    Miss